ENTO
Price
$0.61
Change
-$0.00 (-0.00%)
Updated
Aug 15 closing price
Capitalization
8.72M
RLMD
Price
$0.65
Change
+$0.04 (+6.56%)
Updated
Aug 15 closing price
Capitalization
21.45M
81 days until earnings call
Interact to see
Advertisement

ENTO vs RLMD

Header iconENTO vs RLMD Comparison
Open Charts ENTO vs RLMDBanner chart's image
Entero Therapeutics
Price$0.61
Change-$0.00 (-0.00%)
Volume$337.47K
Capitalization8.72M
Relmada Therapeutics
Price$0.65
Change+$0.04 (+6.56%)
Volume$182.09K
Capitalization21.45M
ENTO vs RLMD Comparison Chart in %
Loading...
ENTO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTO vs. RLMD commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTO is a Hold and RLMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (ENTO: $0.61 vs. RLMD: $0.65)
Brand notoriety: ENTO and RLMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTO: 4% vs. RLMD: 70%
Market capitalization -- ENTO: $8.72M vs. RLMD: $21.45M
ENTO [@Biotechnology] is valued at $8.72M. RLMD’s [@Biotechnology] market capitalization is $21.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTO’s FA Score shows that 1 FA rating(s) are green whileRLMD’s FA Score has 1 green FA rating(s).

  • ENTO’s FA Score: 1 green, 4 red.
  • RLMD’s FA Score: 1 green, 4 red.
According to our system of comparison, both ENTO and RLMD are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTO’s TA Score shows that 6 TA indicator(s) are bullish while RLMD’s TA Score has 6 bullish TA indicator(s).

  • ENTO’s TA Score: 6 bullish, 3 bearish.
  • RLMD’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, both ENTO and RLMD are a good buy in the short-term.

Price Growth

ENTO (@Biotechnology) experienced а +67.17% price change this week, while RLMD (@Biotechnology) price change was +9.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

RLMD is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RLMD($21.4M) has a higher market cap than ENTO($8.72M). RLMD YTD gains are higher at: 24.250 vs. ENTO (-1.929). ENTO has higher annual earnings (EBITDA): -7.42M vs. RLMD (-79.12M). RLMD has more cash in the bank: 27.1M vs. ENTO (59.4K). RLMD has less debt than ENTO: RLMD (256K) vs ENTO (836K). ENTO (0) and RLMD (0) have equivalent revenues.
ENTORLMDENTO / RLMD
Capitalization8.72M21.4M41%
EBITDA-7.42M-79.12M9%
Gain YTD-1.92924.250-8%
P/E Ratio0.03N/A-
Revenue00-
Total Cash59.4K27.1M0%
Total Debt836K256K327%
FUNDAMENTALS RATINGS
ENTO vs RLMD: Fundamental Ratings
ENTO
RLMD
OUTLOOK RATING
1..100
9924
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
3741
P/E GROWTH RATING
1..100
90100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENTO's Valuation (9) in the null industry is in the same range as RLMD (21). This means that ENTO’s stock grew similarly to RLMD’s over the last 12 months.

ENTO's Profit vs Risk Rating (100) in the null industry is in the same range as RLMD (100). This means that ENTO’s stock grew similarly to RLMD’s over the last 12 months.

RLMD's SMR Rating (99) in the null industry is in the same range as ENTO (100). This means that RLMD’s stock grew similarly to ENTO’s over the last 12 months.

ENTO's Price Growth Rating (37) in the null industry is in the same range as RLMD (41). This means that ENTO’s stock grew similarly to RLMD’s over the last 12 months.

ENTO's P/E Growth Rating (90) in the null industry is in the same range as RLMD (100). This means that ENTO’s stock grew similarly to RLMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTORLMD
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
ENTO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DRIO0.450.01
+2.80%
DarioHealth Corp
IFS38.66-0.05
-0.13%
Intercorp Financial Services
SU38.88-0.11
-0.28%
Suncor Energy
SGC12.06-0.12
-0.99%
Superior Group of Companies
SWIM7.60-0.30
-3.80%
Latham Group

RLMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLMD has been loosely correlated with SYRE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RLMD jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLMD
1D Price
Change %
RLMD100%
+6.41%
SYRE - RLMD
36%
Loosely correlated
+0.53%
ENTO - RLMD
36%
Loosely correlated
-0.54%
PRTC - RLMD
31%
Poorly correlated
+2.91%
AVXL - RLMD
31%
Poorly correlated
-1.63%
ZVRA - RLMD
29%
Poorly correlated
+5.96%
More